EP0526200A1 — 2-(Imidazol-1-YL)-2-benzyl-ethylidene-aminoxyalkanoic acid derivatives as thromboxane A2 inhibitors
Assigned to Pfizer Italia SRL · Expires 1993-02-03 · 33y expired
What this patent protects
The present invention relates to 2-(imidazol-1-yl)-2-benzylethylidene-aminoxyalkanoic acids and esters thereof of formula (I) wherein A is a divalent group of formula in which R is hydrogen, halogen, CF 3 , C 1 -C 4 alkoxy, C 1 -C 4 alkylsulfonyl or cyano; …
USPTO Abstract
The present invention relates to 2-(imidazol-1-yl)-2-benzylethylidene-aminoxyalkanoic acids and esters thereof of formula (I) wherein A is a divalent group of formula in which R is hydrogen, halogen, CF 3 , C 1 -C 4 alkoxy, C 1 -C 4 alkylsulfonyl or cyano; R 1 is a) phenyl unsubstituted or substituted by halogen, C 1 -C 4 alkoxy, CF 3 or C 1 -C 4 alkylsulfonyl; b) cyclohexyl; or c) a straight or branched C 1 -C 6 alkyl group; T is a branched or straight C 3 -C 5 alkylene chain; R 2 is hydrogen or C 1 -C 4 alkyl, and the pharmaceutically acceptable salts thereof, which are useful as selective inhibitors of thromboxane A 2 (TxA 2 ) synthesis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.